---
title: "ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240234862.md"
datetime: "2025-05-14T20:47:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240234862.md)
  - [en](https://longbridge.com/en/news/240234862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240234862.md)
---

# ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.42

EPS: As of FY2025 Q1, the actual value is USD -0.42.

EBIT: As of FY2025 Q1, the actual value is USD -15.56 M.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2025 was $15,941,328, compared to $230,970 for the same period in 2024, reflecting an increase of $15,710,358.
-   **General and Administrative Expenses**: Increased to $15,073,548 for the three months ended March 31, 2025, from $132,804 for the same period in 2024, primarily due to stock-based compensation and increased professional services.
-   **Research and Development Expenses**: Increased to $263,093 for the three months ended March 31, 2025, from $10,500 for the same period in 2024.
-   **Sales and Marketing Expenses**: Increased to $219,839 for the three months ended March 31, 2025, from $87,666 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $1,751,528 for the three months ended March 31, 2025, compared to $192,971 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $3,094,438 for the three months ended March 31, 2025, compared to $229,084 for the same period in 2024.

### Unique Metrics

-   **Convertible Notes**: Convertible notes valued at $3,175,354 as of March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: Aspire plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company is conducting clinical trials for its high-dose sublingual aspirin product, aiming for FDA approval by June 30, 2025.
-   **Non-Core Business**: Aspire is developing other products such as sublingual melatonin, vitamins, testosterone, semaglutide, and caffeine products, with plans to launch some by July 1, 2025.
-   **Priority**: Aspire intends to raise additional capital through equity issuances to support its growth and development efforts.

### Related Stocks

- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [As retail stagnates, ad dollars help Walmart stay the course](https://longbridge.com/en/news/296209943.md)
- [Kalshi files for S&P 500 perpetual futures in challenge to traditional exchanges](https://longbridge.com/en/news/296226910.md)
- [Grandfield & Dodd LLC Takes $12.04 Million Position in Corning Incorporated $GLW](https://longbridge.com/en/news/296196821.md)
- [McDonald's Corporation $MCD Shares Sold by Welch & Forbes LLC](https://longbridge.com/en/news/296202808.md)
- [First National Trust Co Sells 5,719 Shares of Intel Corporation $INTC](https://longbridge.com/en/news/296192854.md)